Intervention not reported
Respiratory outcomes: Antibiotic days per patient in past 3 months · children and adults with CF
1 finding from 1 review
Intervention not reported
Adverse events · children and adults with CF
1 finding from 1 review
Intervention not reported
Annualised relapse rate (ARR) (number of relapses per patient per year) · [People] with [Multiple Sclerosis]
1 finding from 1 review
Intervention not reported
Expanded Disability Status Scale (EDSS) score · [People] with [Multiple Sclerosis]
1 finding from 1 review
Intervention not reported
MRI gadolinium‐enhancing T1 lesions · [People] with [Multiple Sclerosis]
1 finding from 1 review
Intervention not reported
Serious adverse events · [People] with [Multiple Sclerosis]
1 finding from 1 review
Intervention not reported
Minor adverse events · [People] with [Multiple Sclerosis]
1 finding from 1 review
Intervention not reported
Stroke and other systemic embolic events · people with atrial fibrillation deemed eligible for long‐term anticoagulant treatment
The intervention leads to lower stroke and other systemic embolic events (high certainty).
1 finding from 1 review
Intervention not reported
All strokes · people with atrial fibrillation deemed eligible for long‐term anticoagulant treatment
The intervention leads to lower all strokes (high certainty).
1 finding from 1 review
Intervention not reported
Major bleedings · people with atrial fibrillation deemed eligible for long‐term anticoagulant treatment
The intervention probably leads to lower major bleedings (moderate certainty).
1 finding from 1 review
Intervention not reported
Intracranial haemorrhages · people with atrial fibrillation deemed eligible for long‐term anticoagulant treatment
The intervention leads to lower intracranial haemorrhages (high certainty).
1 finding from 1 review
Intervention not reported
All‐cause deaths · people with atrial fibrillation deemed eligible for long‐term anticoagulant treatment
The intervention probably leads to lower all‐cause deaths (moderate certainty).
1 finding from 1 review
Supplementation with beta‐carotene + vit C + vit E Overall cognitive functioning · cognitively healthy people in mid and late life
2 findings from 1 review
Incidence of dementia · cognitively healthy people in mid and late life
1 finding from 1 review
Cognitive function · cognitively healthy people in mid and late life
1 finding from 1 review
Incidence of dementia or MCI · cognitively healthy people in mid and late life
1 finding from 1 review
Neovascular AMD · general population
It is very uncertain whether beta‐carotene changes neovascular AMD compared with placebo (very low certainty).
1 finding from 1 review
Geographic atrophy · general population
It is very uncertain whether beta‐carotene changes geographic atrophy compared with placebo (very low certainty).
1 finding from 1 review
Quality of life · general population
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Adverse effects · general population
1 finding from 1 review
no estimate extracted
Studies not reported
High